Cancer Diagnostics Market by Product (Consumables and Instruments), Application (Breast Cancer, Breast Cancer, Lung Cancer, Blood Cancer, Colorectal Cancer, Skin Cancer, Ovarian Cancer, Prostate Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Cervical Cancer, and Others), and End Use (Hospitals & Clinics, Diagnostic Laboratories, Diagnostic Centers, and Research Institutes): Opportunity Analysis and Industry Forecast, 2021–2028
- ALL4621670
- 239 Pages
- May 2021
- Medical Devices
Cancer diagnostics is the process of detecting biomarkers, proteins, and other indicators that contribute to the detection of a cancerous tumor. Effective diagnostic testing is used to confirm or rule out the presence of infection, monitor disease severity, and plan & evaluate clinical outcomes. Diagnostic procedures for cancer may include imaging, laboratory tests (including tests for tumor markers), endoscopic examination, tumor biopsy, surgery, or genetic testing.
The major factor that contributes to the growth of the cancer diagnostics market includes surge in government initiatives and other private organizations to spread awareness regarding early diagnosis and prevention of cancer, which is anticipated to boost the growth of the market in the coming years. Furthermore, the growth in the number of diagnostics laboratories in developed countries is expected to drive the market growth in the next few years. Increase in incidences and prevalence of various types of cancer, such as breast cancer and lung cancer, are expected to drive the growth of the market.
However, huge cost associated with diagnostic imaging system and development of different diagnostic approaches for various cancer mutations may hinder the growth of the market. Conversely, increase in emphasis over health & safety regulations and surge in popularity of yoga and other health related practices will act as a growth opportunity during the forecast period.
The cancer diagnostics market is segmented on the basis of basis of product, application, and end use to provide a detailed assessment of the market. By product, the market is bifurcated into consumables and instruments. Further, consumables are divided into antibodies, kits & reagents, probes, and other consumables. Instruments include pathology-based instruments, imaging instruments, and biopsy instruments. On the basis of application, the market is fragmented into breast cancer, lung cancer, blood cancer, colorectal cancer, skin cancer, ovarian cancer, prostate cancer, kidney cancer, liver cancer, pancreatic cancer, cervical cancer, and others. Based on end use, the market is classified into hospitals & clinics, diagnostic laboratories, diagnostic imaging centers, and research institutes. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2020 to 2028, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of factors that drive and restrain the growth of the market is provided.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Product
• Consumables
o Antibodies
o Kits & Reagents
o Probes
o Other consumables
• Instruments
o Pathology-based Instruments
o Imaging Instruments
o Biopsy Instruments
By Application
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Lung Cancer
• Prostate Cancer
• Skin Cancer
• Blood Cancer
• Kidney Cancer
• Liver Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others
By End Use
• Hospitals & Clinics
• Diagnostic Laboratories
• Diagnostic Imaging Centers
• Research Institutes
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Abbott Laboratories
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Roche Holdings AG (F. Hoffmann-La Roche Ltd.)
• Danaher Corporation (GE Healthcare)
• Hologic, Inc.
• Koninklijke Philips N.V. (Philips Healthcare)
• Qiagen N.V.
• Siemens Healthcare GmbH
• Thermo Fisher Scientific Inc.
1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter's five forces analysis
3.3.1.Bargaining power of buyers
3.3.2.Bargaining power of suppliers
3.3.3.Thereat of new entrants
3.3.4.Threat of substitutes
3.3.5.Intensity of competitive rivalry
3.4.Top player positioning, 2019
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rise in incidences and prevalence of various cancer types
3.5.1.2.Increase in technological advancements
3.5.1.3.Government initiatives and other organization to spread awareness about cancer
3.5.1.4.Growing number of diagnostics laboratories In developed countries
3.5.2.Restraints
3.5.2.1.Huge cost associated with diagnostic imaging system
3.5.2.2.Risk related with high radiation exposure affecting use of CT scanner
3.5.3.Opportunities
3.5.3.1.Development of diagnostic approaches for various cancer mutation
3.6.Impact Analysis
3.7.Impact Analysis of the Covid-19 on Cancer Diagnostics Market
CHAPTER 4:CANCER DIAGNOSTICS MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Consumables
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.2.4.Market size and forecast, by type
4.2.5.Antibodies
4.2.5.1.Market size and forecast
4.2.6.Kits & Reagents
4.2.6.1.Market size and forecast
4.2.7.Probes
4.2.7.1.Market size and forecast
4.2.8.Other consumables
4.2.8.1.Market size and forecast
4.3.Instruments
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.3.4.Market size and forecast, by type
4.3.5.Pathology-based Instruments
4.3.5.1.Market size and forecast
4.3.6.Imaging Instruments
4.3.6.1.Market size and forecast
4.3.7.Biopsy Instruments
4.3.7.1.Market size and forecast
CHAPTER 5:CANCER DIAGNOSTICS MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Breast Cancer
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Colorectal Cancer
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Cervical Cancer
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Lung Cancer
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Prostate Cancer
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
5.7.Skin Cancer
5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country
5.8.Blood Cancer
5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country
5.9.Kidney Cancer
5.9.1.Market size and forecast, by region
5.9.2.Market analysis, by country
5.10.Liver Cancer
5.10.1.Market size and forecast, by region
5.10.2.Market analysis, by country
5.11.Pancreatic Cancer
5.11.1.Market size and forecast, by region
5.11.2.Market analysis, by country
5.12.Ovarian Cancer
5.12.1.Market size and forecast, by region
5.12.2.Market analysis, by country
5.13.Others
5.13.1.Market size and forecast, by region
5.13.2.Market analysis, by country
CHAPTER 6:CANCER DIAGNOSTICS MARKET, BY END USE
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospital and Clinics
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Diagnostic Laboratories
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Diagnostic Imaging Centers
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
6.5.Research Institutes
6.5.1.Market size and forecast, by region
6.5.2.Market analysis, by country
CHAPTER 7:CANCER DIAGNOSTICS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.2.1.U.S.
7.2.2.1.1.U.S. cancer diagnostics market, by product
7.2.2.1.2.U.S. cancer diagnostics market, by application
7.2.2.1.3.U.S. cancer diagnostics market, by end use
7.2.2.2.Canada
7.2.2.2.1.Canada cancer diagnostics market, by product
7.2.2.2.2.Canada cancer diagnostics market, by application
7.2.2.2.3.Canada cancer diagnostics market, by end use
7.2.2.3.Mexico
7.2.2.3.1.Mexico cancer diagnostics market, by product
7.2.2.3.2.Mexico cancer diagnostics market, by application
7.2.2.3.3.Mexico cancer diagnostics market, by end use
7.2.3.North America market size and forecast, by product
7.2.4.North America market size and forecast, by application
7.2.5.North America market size and forecast, by end use
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country
7.3.2.1.Germany
7.3.2.1.1.Germany cancer diagnostics market, by product
7.3.2.1.2.Germany cancer diagnostics market, by application
7.3.2.1.3.Germany cancer diagnostics market, by end use
7.3.2.2.France
7.3.2.2.1.France cancer diagnostics market, by product
7.3.2.2.2.France cancer diagnostics market, by application
7.3.2.2.3.France cancer diagnostics market, by end use
7.3.2.3.UK
7.3.2.3.1.UK cancer diagnostics market, by product
7.3.2.3.2.UK cancer diagnostics market, by application
7.3.2.3.3.UK cancer diagnostics market, by end use
7.3.2.4.Italy
7.3.2.4.1.Italy cancer diagnostics market, by product
7.3.2.4.2.Italy cancer diagnostics market, by application
7.3.2.4.3.Italy cancer diagnostics market, by end use
7.3.2.5.Spain
7.3.2.5.1.Spain cancer diagnostics market, by product
7.3.2.5.2.Spain cancer diagnostics market, by application
7.3.2.5.3.Spain cancer diagnostics market, by end use
7.3.2.6.Rest of Europe
7.3.2.6.1.Rest of Europe cancer diagnostics market, by product
7.3.2.6.2.Rest of Europe cancer diagnostics market, by application
7.3.2.6.3.Rest of Europe cancer diagnostics market, by end use
7.3.3.Europe market size and forecast, by product
7.3.4.Europe market size and forecast, by application
7.3.5.Europe market size and forecast, by end use
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.2.1.Japan
7.4.2.1.1.Japan cancer diagnostics market, by product
7.4.2.1.2.Japan cancer diagnostics market, by application
7.4.2.1.3.Japan cancer diagnostics market, by end use
7.4.2.2.China
7.4.2.2.1.China cancer diagnostics market, by product
7.4.2.2.2.China cancer diagnostics market, by application
7.4.2.2.3.China cancer diagnostics market, by end use
7.4.2.3.Australia
7.4.2.3.1.Australia cancer diagnostics market, by product
7.4.2.3.2.Australia cancer diagnostics market, by application
7.4.2.3.3.Australia cancer diagnostics market, by end use
7.4.2.4.India
7.4.2.4.1.India cancer diagnostics market, by product
7.4.2.4.2.India cancer diagnostics market, by application
7.4.2.4.3.India cancer diagnostics market, by end use
7.4.2.5.South Korea
7.4.2.5.1.South Korea cancer diagnostics market, by product
7.4.2.5.2.South Korea cancer diagnostics market, by application
7.4.2.5.3.South Korea cancer diagnostics market, by end use
7.4.2.6.Rest of Asia-Pacific
7.4.2.6.1.Rest of Asia-Pacific cancer diagnostics market, by product
7.4.2.6.2.Rest of Asia-Pacific cancer diagnostics market, by application
7.4.2.6.3.Rest of Asia-Pacific cancer diagnostics market, by end use
7.4.3.Asia-Pacific market size and forecast, by product
7.4.4.Asia-Pacific market size and forecast, by application
7.4.5.Asia-Pacific market size and forecast, by end use
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country
7.5.2.1.Brazil
7.5.2.1.1.Brazil cancer diagnostics market, by product
7.5.2.1.2.Brazil cancer diagnostics market, by application
7.5.2.1.3.Brazil cancer diagnostics market, by end use
7.5.2.2.Saudi Arabia
7.5.2.2.1.Saudi Arabia cancer diagnostics market, by product
7.5.2.2.2.Saudi Arabia cancer diagnostics market, by application
7.5.2.2.3.Saudi Arabia cancer diagnostics market, by end use
7.5.2.3.South Africa
7.5.2.3.1.South Africa cancer diagnostics market, by product
7.5.2.3.2.South Africa cancer diagnostics market, by application
7.5.2.3.3.South Africa cancer diagnostics market, by end use
7.5.2.4.Rest of LAMEA
7.5.2.4.1.Rest of LAMEA cancer diagnostics market, by product
7.5.2.4.2.Rest of LAMEA cancer diagnostics market, by application
7.5.2.4.3.Rest of LAMEA cancer diagnostics market, by end use
7.5.3.LAMEA market size and forecast, by product
7.5.4.LAMEA market size and forecast, by application
7.5.5.LAMEA market size and forecast, by end use
CHAPTER 8:COMPANY PROFILES
8.1.ABBOTT LABORATORIES
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.BECTON, DICKINSON AND COMPANY
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.Bio-Rad Laboratories, Inc.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.Roche Holdings AG (F. Hoffmann-La Roche Ltd.)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.Danaher Corporation (GE Healthcare)
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.Hologic, Inc.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.KONINKLIJKE PHILIPS N.V. (Philips Healthcare)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.Qiagen N.V.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.Siemens Healthcare GmbH
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.Thermo Fisher Scientific
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
TABLE 01.GLOBAL CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
TABLE 02.CONSUMABLES CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 03.CONSUMABLES CANCER DIAGNOSTICS MARKET, BY TYPE, 2020-2028, ($MILLION)
TABLE 04.INSTRUMENTS CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 05.INSTRUMENTS CANCER DIAGNOSTICS MARKET, BY TYPE, 2020-2028, ($MILLION)
TABLE 06.GLOBAL CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 07.BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 08.COLORECTAL CANCER, CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 09.CERVICAL CANCER, CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 10.LUNG CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 11.PROSTSATE CANCER, CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 12.SKIN CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 13.BLOOD CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 14.KIDNEY CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 15.LIVER CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 16.PANCREATIC CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 17.OVARIAN CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 18.OTHERS CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 19.GLOBAL CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028 ($MILLION)
TABLE 20.HOSPITALS AND CLINICS, CANCER DIAGNOSTICS MARKET, BY REGION, 2020–2028 ($MILLION)
TABLE 21.DIAGNOSTICS LABORATORIES CANCER DIAGNOSTICS MARKET, BY REGION, 2020–2028 ($MILLION)
TABLE 22.DIAGNOSTICS IMAGING CENTERS CANCER DIAGNOSTICS MARKET, BY REGION, 2020–2028 ($MILLION)
TABLE 23.RESEARCH INSTITUTES CANCER DIAGNOSTICS MARKET, BY REGION, 2020–2028 ($MILLION)
TABLE 24.CANCER DIAGNOSTICS MARKET, BY REGION, 2020–2028 ($MILLION)
TABLE 25.NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 26.U.S. CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 27.U.S. CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 28.U.S. CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 29.CANADA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 30.CANADA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 31.CANADA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 32.MEXICO CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 33.MEXICO CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 34.MEXICO CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 35.NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 36.NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 37.NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 38.EUROPE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 39.GERMANY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 40.GERMANY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 41.GERMANY CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 42.FRANCE CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 43.FRANCE CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 44.FRANCE CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 45.UK CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 46.UK CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 47.UK CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 48.ITALY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 49.ITALY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 50.ITALY CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 51.SPAIN CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 52.SPAIN CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 53.SPAIN CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 54.REST OF EUROPE CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 55.REST OF EUROPE CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 56.REST OF EUROPE CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 57.EUROPE CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 58.EUROPE CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 59.EUROPE CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 60.ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 61.JAPAN CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 62.JAPAN CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 63.JAPAN CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 64.CHINA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 65.CHINA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 66.CHINA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 67.AUSTRALIA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 68.AUSTRALIA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 69.AUSTRALIA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 70.INDIA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 71.INDIA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 72.INDIA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 73.SOUTH KOREA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 74.SOUTH KOREA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 75.SOUTH KOREA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 76.REST OF ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 77.REST OF ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 78.REST OF ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 79.ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 80.ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 81.ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 82.LAMEA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 ($MILLION)
TABLE 83.LAMEA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020–2028 (UNITS)
TABLE 84.BRAZIL CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 85.BRAZIL CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 86.BRAZIL CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 87.SAUDI ARABIA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 88.SAUDI ARABIA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 89.SAUDI ARABIA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 90.SOUTH AFRICA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 91.SOUTH AFRICA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 92.SOUTH AFRICA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 93.REST OF LAMEA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 94.REST OF LAMEA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 95.REST OF LAMEA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 96.LAMEA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020–2028
TABLE 97.LAMEA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020–2028
TABLE 98.LAMEA CANCER DIAGNOSTICS MARKET, BY END USE, 2020–2028
TABLE 99.ABBOTT: COMPANY SNAPSHOT
TABLE 100.ABBOTT: OPERATING SEGMENT
TABLE 101.ABBOTT LABORATORIES PLC: PRODUCT PORTFOLIO
TABLE 102.BD: SNAPSHOT
TABLE 103.BD: OPERATING SEGMENTS
TABLE 104.BD: PRODUCT PORTFOLIO
TABLE 105.BD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 106.BIO-RAD: COMPANY SNAPSHOT
TABLE 107.MYRIAD: OERATING SEGMENT
TABLE 108.BIO-RAD: PRODUCT PORTFOLIO
TABLE 109.BIO-RAD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 110.ROCHE: COMPANY SNAPSHOT
TABLE 111.ROCHE: OPERATING SEGMENTS
TABLE 112.ROCHE: PRODUCT PORTFOLIO
TABLE 113.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114.DANAHER: COMPANY SNAPSHOT
TABLE 115.DANAHER: OPERATING SEGMENT
TABLE 116.DANAHER: PRODUCT PORTFOLIO
TABLE 117.DANAHER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 118.HOLOGIC: COMPANY SNAPSHOT
TABLE 119.HOLOGIC: OERATING SEGMENT
TABLE 120.HOLOGIC: PRODUCT PORTFOLIO
TABLE 121.HOLOGIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 122.PHILIPS: COMPANY SNAPSHOT
TABLE 123.PHILIPS: OERATING SEGMENT
TABLE 124.PHILIPS: PRODUCT PORTFOLIO
TABLE 125.PHILIPS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 126.QIAGEN: COMPANY SNAPSHOT
TABLE 127.QIAGEN: PRODUCT PORTFOLIO
TABLE 128.QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 129.SIEMENS: COMPANY SNAPSHOT
TABLE 130.SIEMENS: OERATING SEGMENTS
TABLE 131.SIEMENS: PRODUCT PORTFOLIO
TABLE 132.SIEMENS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 133.THERMO: COMPANY SNAPSHOT
TABLE 134.THERMO: OPERATING SEGMENTS
TABLE 135.THERMO: PRODUCT PORTFOLIO
TABLE 136.THERMO: KEY STRATEGIC MOVES AND DEVELOPMENTS
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
